FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079641631> ?p ?o ?g. }

• W2079641631 endingPage "9719" @default.
• W2079641631 startingPage "9709" @default.
• W2079641631 abstract "The heterogeneously glycosylated 81-residue tryptic tandem repeat glycopeptide from porcine submaxillary mucin (PSM) has been isolated and its glycosylation pattern determined by amino acid sequencing. Key to these studies is the ability to trim the structurally heterogeneous PSM oligosaccharide side chains to homogeneous GalNAc monosaccharide side chains by mild trifluoromethanesulfonic acid treatment. Trypsin treatment of trifluoromethanesulfonic acid-treated PSM releases the 81-residue tandem repeat as an ensemble of 81-residue glycopeptides with different glycosylation patterns. Automated amino acid sequencing using Edman degradative chemistry of the repeat was used to determine the extent of glycosylation of nearly every Ser and Thr residue. The Thr residues are all highly glycosylated within the range of 73-90%, giving an average Thr glycosylation of 83%. In contrast, the Ser residues display a wide range of glycosylations, ranging between 33 and 95%, giving an average Ser glycosylation of 74%. These data are consistent with the known elevated glycosylation of Thr peptides over Ser peptides for the porcine UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyltransferase. It is also observed that the extent of glycosylation of the repeat correlates poorly with published predictive methods. An examination of the sequences surrounding the glycosylation sites reveals that nearly all of the highly glycosylated sites have a penultimate Gly residue, whereas those that are less highly glycosylated have medium to large side chain penultimate residues. As observed by others, glycosylation also appears to be modulated by the presence of Pro residues. On the basis of these findings we suggest that the acceptor peptide binds the transferase in a β-like conformation and that penultimate residue side chain steric interactions may play a role in determining extent that a given Ser or Thr is glycosylated. A model for the GalNAc transferase peptide binding site is proposed. The heterogeneously glycosylated 81-residue tryptic tandem repeat glycopeptide from porcine submaxillary mucin (PSM) has been isolated and its glycosylation pattern determined by amino acid sequencing. Key to these studies is the ability to trim the structurally heterogeneous PSM oligosaccharide side chains to homogeneous GalNAc monosaccharide side chains by mild trifluoromethanesulfonic acid treatment. Trypsin treatment of trifluoromethanesulfonic acid-treated PSM releases the 81-residue tandem repeat as an ensemble of 81-residue glycopeptides with different glycosylation patterns. Automated amino acid sequencing using Edman degradative chemistry of the repeat was used to determine the extent of glycosylation of nearly every Ser and Thr residue. The Thr residues are all highly glycosylated within the range of 73-90%, giving an average Thr glycosylation of 83%. In contrast, the Ser residues display a wide range of glycosylations, ranging between 33 and 95%, giving an average Ser glycosylation of 74%. These data are consistent with the known elevated glycosylation of Thr peptides over Ser peptides for the porcine UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyltransferase. It is also observed that the extent of glycosylation of the repeat correlates poorly with published predictive methods. An examination of the sequences surrounding the glycosylation sites reveals that nearly all of the highly glycosylated sites have a penultimate Gly residue, whereas those that are less highly glycosylated have medium to large side chain penultimate residues. As observed by others, glycosylation also appears to be modulated by the presence of Pro residues. On the basis of these findings we suggest that the acceptor peptide binds the transferase in a β-like conformation and that penultimate residue side chain steric interactions may play a role in determining extent that a given Ser or Thr is glycosylated. A model for the GalNAc transferase peptide binding site is proposed." @default.
• W2079641631 created "2016-06-24" @default.
• W2079641631 creator A5016398123 @default.
• W2079641631 creator A5018543286 @default.
• W2079641631 creator A5084403760 @default.
• W2079641631 date "1997-04-01" @default.
• W2079641631 modified "2023-10-15" @default.
• W2079641631 title "Determination of the Site-specific O-Glycosylation Pattern of the Porcine Submaxillary Mucin Tandem Repeat Glycopeptide" @default.
• W2079641631 cites W1494626566 @default.
• W2079641631 cites W1570729505 @default.
• W2079641631 cites W1578270753 @default.
• W2079641631 cites W1578452610 @default.
• W2079641631 cites W1583697018 @default.
• W2079641631 cites W1589242674 @default.
• W2079641631 cites W1589735909 @default.
• W2079641631 cites W1607611516 @default.
• W2079641631 cites W1608912555 @default.
• W2079641631 cites W1870828328 @default.
• W2079641631 cites W1967150795 @default.
• W2079641631 cites W1967504750 @default.
• W2079641631 cites W1970252025 @default.
• W2079641631 cites W1974230155 @default.
• W2079641631 cites W1974384968 @default.
• W2079641631 cites W1975534674 @default.
• W2079641631 cites W1975587236 @default.
• W2079641631 cites W1976666998 @default.
• W2079641631 cites W1980726194 @default.
• W2079641631 cites W1988126373 @default.
• W2079641631 cites W1995773911 @default.
• W2079641631 cites W1997210478 @default.
• W2079641631 cites W1997263031 @default.
• W2079641631 cites W2007582393 @default.
• W2079641631 cites W2008881680 @default.
• W2079641631 cites W2012624595 @default.
• W2079641631 cites W2014875362 @default.
• W2079641631 cites W2024117381 @default.
• W2079641631 cites W2036048311 @default.
• W2079641631 cites W2041599982 @default.
• W2079641631 cites W2043326396 @default.
• W2079641631 cites W2049734140 @default.
• W2079641631 cites W2056193494 @default.
• W2079641631 cites W2057197299 @default.
• W2079641631 cites W2068922559 @default.
• W2079641631 cites W2075028117 @default.
• W2079641631 cites W2081634183 @default.
• W2079641631 cites W2089645418 @default.
• W2079641631 cites W2094803824 @default.
• W2079641631 cites W2094811729 @default.
• W2079641631 cites W2099675490 @default.
• W2079641631 cites W2125568624 @default.
• W2079641631 cites W2129232972 @default.
• W2079641631 cites W2156276857 @default.
• W2079641631 cites W4230952644 @default.
• W2079641631 cites W88725230 @default.
• W2079641631 doi "https://doi.org/10.1074/jbc.272.15.9709" @default.
• W2079641631 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9092502" @default.
• W2079641631 hasPublicationYear "1997" @default.
• W2079641631 type Work @default.
• W2079641631 sameAs 2079641631 @default.
• W2079641631 citedByCount "84" @default.
• W2079641631 countsByYear W20796416312012 @default.
• W2079641631 countsByYear W20796416312014 @default.
• W2079641631 countsByYear W20796416312015 @default.
• W2079641631 countsByYear W20796416312016 @default.
• W2079641631 countsByYear W20796416312017 @default.
• W2079641631 countsByYear W20796416312021 @default.
• W2079641631 countsByYear W20796416312022 @default.
• W2079641631 countsByYear W20796416312023 @default.
• W2079641631 crossrefType "journal-article" @default.
• W2079641631 hasAuthorship W2079641631A5016398123 @default.
• W2079641631 hasAuthorship W2079641631A5018543286 @default.
• W2079641631 hasAuthorship W2079641631A5084403760 @default.
• W2079641631 hasBestOaLocation W20796416311 @default.
• W2079641631 hasConcept C104317684 @default.
• W2079641631 hasConcept C108625454 @default.
• W2079641631 hasConcept C137610392 @default.
• W2079641631 hasConcept C167625842 @default.
• W2079641631 hasConcept C179264091 @default.
• W2079641631 hasConcept C185592680 @default.
• W2079641631 hasConcept C206212055 @default.
• W2079641631 hasConcept C2777313579 @default.
• W2079641631 hasConcept C2781338088 @default.
• W2079641631 hasConcept C30324644 @default.
• W2079641631 hasConcept C501593827 @default.
• W2079641631 hasConcept C55493867 @default.
• W2079641631 hasConcept C87933860 @default.
• W2079641631 hasConceptScore W2079641631C104317684 @default.
• W2079641631 hasConceptScore W2079641631C108625454 @default.
• W2079641631 hasConceptScore W2079641631C137610392 @default.
• W2079641631 hasConceptScore W2079641631C167625842 @default.
• W2079641631 hasConceptScore W2079641631C179264091 @default.
• W2079641631 hasConceptScore W2079641631C185592680 @default.
• W2079641631 hasConceptScore W2079641631C206212055 @default.
• W2079641631 hasConceptScore W2079641631C2777313579 @default.
• W2079641631 hasConceptScore W2079641631C2781338088 @default.
• W2079641631 hasConceptScore W2079641631C30324644 @default.
• W2079641631 hasConceptScore W2079641631C501593827 @default.
• W2079641631 hasConceptScore W2079641631C55493867 @default.

• next